Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)46.25
  • Today's Change-2.15 / -4.44%
  • Shares traded4.79k
  • 1 Year change-31.89%
  • Beta0.6430
Data delayed at least 15 minutes, as of Jun 14 2024 16:36 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

  • Revenue in EUR (TTM)77.70m
  • Net income in EUR75.80m
  • Incorporated2012
  • Employees238.00
  • Location
    Formycon AGFraunhoferstrasse 15MARTINSRIED 82152GermanyDEU
  • Phone+49 89 864667100
  • Fax+49 89 864667110
  • Websitehttps://www.formycon.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PharmaSGP Holding SE107.29m18.11m271.20m89.0014.976.079.862.531.511.518.953.730.78181.069.121,205,539.0013.2013.7016.4419.9890.9390.2016.8817.562.1912.340.6237--17.8010.7837.172.1625.88--
Formycon AG77.70m75.80m816.63m238.009.851.4810.5110.514.704.704.8431.320.0891104.803.56326,453.808.695.879.336.3330.0028.5497.5539.760.9621-0.01890.01760.0082.8312.47110.5960.5881.87--
Eckert & Ziegler SE255.78m34.32m949.35m1.07k27.233.9719.513.711.651.4412.2711.290.58343.084.72237,931.207.988.509.7510.2348.4248.6113.6814.002.2421.890.191935.0910.747.84-2.8413.2233.82-30.12
Biotest AG782.60m176.90m1.33bn2.43k9.173.07--1.694.474.4719.7813.340.59361.143.83322,588.6013.42-0.069316.72-0.07944.2428.4322.60-0.15270.91395.340.5677--32.6511.33490.89---9.36--
Evotec SE776.60m-90.69m1.49bn5.06k--1.35--1.92-0.5124-0.51244.396.24------153,447.10---0.0064---0.007620.1624.51-11.68-0.01781.79-2.090.36190.003.9915.7952.23--50.62--
Dermapharm Holding SE1.11bn56.58m1.95bn3.50k34.573.3611.931.751.051.0520.6910.810.51371.259.68318,823.002.518.683.0110.0663.3261.944.8912.310.75172.700.636754.6910.7914.68-53.54-3.709.85--
MorphoSys AG203.50m-456.34m2.49bn464.00------12.23-12.54-12.655.79-6.950.10021.864.58388,358.00-22.47-10.25-27.58-11.6183.8985.92-224.25-78.531.38-------14.3725.53-25.60--3.11--
Data as of Jun 14 2024. Currency figures normalised to Formycon AG's reporting currency: Euro EUR

Institutional shareholders

10.01%Per cent of shares held by top holders
HolderShares% Held
Active Ownership Corp SARLas of 31 Dec 20231.07m6.09%
Norges Bank Investment Managementas of 31 Dec 2023151.00k0.86%
ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 30 Apr 2024140.40k0.80%
Lupus alpha Asset Management AGas of 30 Jun 2023118.00k0.67%
Plutos Verm�gensverwaltung AGas of 30 Sep 2023110.00k0.62%
MPPM Manfred Piontke Portfolio Management e.K.as of 30 Sep 202341.00k0.23%
Cr�dit Mutuel Asset Management SAas of 29 Dec 202336.48k0.21%
TBF Global Asset Management GmbHas of 31 Mar 202435.55k0.20%
BlackRock Fund Advisorsas of 09 May 202431.92k0.18%
Ehrke & L�bberstedt AGas of 31 Mar 202429.08k0.17%
More ▼
Data from 30 Sep 2023 - 31 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.